☆
Watchlist
Log in
Sign-up
Healius Ltd (hls) Logo

Healius Ltd (HLS)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

HLS Chart

Snapshot

HLS's Principal Activity is the provision of pathology, imaging and day hospitals and also facilities & support services to general practitioners, radiologists and other healthcare professionals.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) +8.22%
vs ASX 200 (1yr) +4.50%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 159 of 2,413
Sector Rank 10 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies SNZ / ANN / TLX
EPS $0.373
DPS $0.2675
Book Value Per Share $3.10

Broker Consensus

Breakdown 10 Buy · 8 Hold · 0 Sell
Recommendation Buy
Last Updated 09/05/22

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Healius Limited (HLS) is a healthcare company which provides facilities and support services to independent general practitioners, radiologists and a range of other healthcare professionals. Healius has three main businesses - Pathology, Imaging and Day Hospitals.

Incorporation Details

Incorporated Incorporated on 17 May 1994 in Victoria, Australia.

Corporate Details

Head Office St Leonards NSW 2065
Website www.healius.com.au
Registry Computershare
Auditor Ernst & Young
Date Listed 3 Jul 1998

Upcoming Calendar (Forecasted)

Date Event
29/08/2022 Report (Prelim)
13/09/2022 Report (Annual)
07/02/2023 Report (Interim)
22/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
24/03/2022 $0.10 100% $0.1429 Interim 05/04/2022
24/03/2022 $0.10 100% $0.1429 Interim 15/04/2022
13/09/2021 $0.0675 100% $0.0964 Final 08/10/2021
25/03/2021 $0.065 100% $0.0929 Interim 15/04/2021
26/03/2020 $0.026 100% $0.0371 Interim 15/10/2020
29/08/2019 $0.034 100% $0.0486 Final 27/09/2019
15/03/2019 $0.038 100% $0.0543 Interim 26/03/2019
27/08/2018 $0.055 100% $0.0786 Final 17/09/2018
Show All

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.2675
Gross DPS(TTM) $0.3821
Dividend yield
Gross yield
Payout Ratio 66%
DRP Yes
DRP Features no discount

Directors & Management

Directors & Management

Name Title Since Bio
Professor John Mattick Non-Executive Director Mar 2022

Professor John Mattick

Non-Executive Director

Professor Mattick is currently SHARP Professor of RNA Biology at UNSW Sydney. He was previously Chief Executive of Genomics England (2018-2019), and Director of the Garvan Institute of Medical Research in Sydney (2012-2018). He was appointed an Officer of the Order of Australia in 2001 for services to scientific research in the fields of molecular biology, genetics and biotechnology, particularly through the development and administration of research institutes and the Australian Genome Research Facility at the University of Queensland, where he was Foundation Director. He has over 300 research publications which have been cited over 80,000 times. He has been a member of the Australian Health Ethics Committee (AHEC) and the Research Committee of the National Health and Medical Research Council, and was involved in the development of the National Statement on the Ethical Conduct of Research involving Humans, the joint Australian Law Reform Commission (ALRC) / AHEC Commonwealth Inquiry into the Protection of Human Genetic Information, the Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology, and the ALRC Reports on Gene Patenting and Genetic Privacy. He was also Chair of the Queensland Studies Authority. He has received numerous awards including the Advance Global Impact Award (2019), the University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Research (2014), the Human Genome Organisation Chen Medal for Distinguished Academic Achievement in Human Genetics and Genomic Research (2012), the International Union of Biochemistry and Molecular Biology Medal (2011), and the inaugural Gutenberg Chair at the University of Strasbourg (2007).
Ms Kathryn (Kate) Mary McKenzie Non-Executive Director Feb 2021

Ms Kathryn (Kate) Mary McKenzie

Non-Executive Director

Ms McKenzie was appointed as a Non-executive Director effective 25 February 2021. She was appointed as a member of the People & Governance Committee and as a member of the Risk Management Committee on the same date. She is a highly experienced Chief Executive Officer and Non-executive Director with experience in large change management. After starting her career in the public sector, she joined Telstra in 2004 as Group Managing Director Regulatory, Public Policy & Communications. In her 12 years at Telstra, she held a range of executive roles in strategy, marketing, products and wholesale. Prior to leaving Telstra, she was Chief Operating Officer, responsible for networks, IT, field services, property and NBN relations and delivery. In 2017 she was appointed Chief Executive Officer of Chorus, a New Zealand listed telecommunications company. She is passionate about innovation and technology, and co-founded muru-D, an incubator which has produced 44 graduating companies, with 41 still in operation; Gurrowa, a co-creation lab, and partnerships with universities, such as investment in Quantum Computing with the University of New South Wales

Ms Jennifer (Jenny) Mitchell Macdonald Non-Executive Director Nov 2020

Ms Jennifer (Jenny) Mitchell Macdonald

Non-Executive Director

Ms Macdonald was appointed as a Non-executive Director and Chair of the Audit Committee effective 3 November 2020. She has a strong background in financial and general management roles across a range of industry sectors including fast moving consumer goods, resources, travel and digital media. she commenced her career with KPMG, working in the London and Melbourne offices in a number of practice areas, including audit, she spent more than ten years with that firm. After gaining experience in the resources sector, she held executive roles in the travel and tourism industries and digital media at Flight Centre and REA Group. From 2014-2016 Jenny was the Chief Financial Officer and then Interim Chief Executive Officer of Helloworld, an ASX-listed multi-channel travel company.

Ms Alison Stephenson Company Secretary Aug 2019
Ms Sally Evans Non-Executive Director Aug 2018

Ms Sally Evans

Non-Executive Director

Ms Evans was appointed as a Non-executive Director in August 2018, also being appointed as a member of the Nomination and Remuneration Committee and the Risk Management Committee. On 19 August 2019, she was appointed as Chair of the newly renamed People & Governance Committee. Sally has over 30 years' experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. She has served as a Non-executive Director of Gateway Lifestyle Operations Limited.

Dr Malcolm Parmenter Chief Executive Officer,Managing Director Sep 2017

Dr Malcolm Parmenter

Chief Executive Officer,Managing Director

Dr Parmenter joined Healius as Managing Director and Chief Executive Officer (CEO) in September 2017. He has a wealth of knowledge and practical experience in the operation of frontline care, with over nine years' tenure as CEO of Independent Practitioner Network Limited (IPN), both as a listed company and under the ownership of Sonic Healthcare Limited, and subsequently two years as CEO of Sonic Clinical Services. He has a strong understanding of healthcare delivery, both in Australia and abroad, and has spent more than 20 years as a General Practitioner.

Mr Gordon Richard Davis Non-Executive Director Aug 2015

Mr Gordon Richard Davis

Non-Executive Director

Mr Davis was appointed as a member of the Risk Management Committee and as Chair of the Risk Management Committee on 19 August 2019, at which time he ceased as Audit Committee Chair but remained a member of that committee. Prior to becoming a Non-executive Director, Gordon was Managing Director of AWB Limited between 2006 and 2010. He has also served in a senior capacity on various industry associations.

Mr Charles Tilley Company Secretary Feb 2015
Mr Robert Hubbard Non-Executive Director,Non-Executive Chairman Dec 2014

Mr Robert Hubbard

Non-Executive Director,Non-Executive Chairman

Mr Hubbard was a member of the Risk Management Committee up to that date. Rob Birmingham. He previously held partnership positions in the accounting, corporate finance, assurance and audit divisions of PricewaterhouseCoopers and acted as external auditor for some of Australia's largest ASX-listed companies.

Dr Paul Francis Jones Non-Executive Director Nov 2010

Dr Paul Francis Jones

Non-Executive Director

Dr Jones was appointed as a Non-executive Director in November 2010. During FY 2021, he was a member of the Audit Committee (from 25 February 2021), the People & Governance Committee and the Risk Management Committee (the latter until 25 February 2021). He has over 35 years' experience in a broad range of general medical practice, including 15 years' experience in Healius Group medical centres. He originally trained at the Repatriation and General Hospital, Concord NSW and subsequently at Calvary Public Hospital, Bruce ACT. He has been a Director and Federal Councillor of the Australian Medical Association (AMA), a past President of AMA ACT and a member of the Federal AMA Council of General Practice. He was formerly a general practitioner adviser to Calvary Public Hospital and held roles as GPVMO and Director, Medical Education Program. He is a former Chair of ACT GP Workforce Working Group and was a member of the ACT Health Minister's GP Task Force in 2009

Dean Lewsam Chief Executive Imaging N/A
John McKechnie Chief Executive Pathology N/A
Maxine Jaquet Chief Financial Officer & Chief Operating Officer (CFO & COO) N/A
Show All

Director Transactions

HLS directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
23/02/22 Gordon Davis Buy +8,032 $4.98 $40,000 Conversion of securities
23/02/22 Gordon Davis Exercise 8,032 $4.98 $40,000 Conversion of securities
23/02/22 Sally Evans Buy +6,024 $4.98 $30,000 Conversion of securities
23/02/22 Sally Evans Exercise 6,024 $4.98 $30,000 Conversion of securities
23/02/22 Robert Hubbard Buy +10,040 $4.98 $50,000 Conversion of securities
23/02/22 Robert Hubbard Exercise 10,040 $4.98 $50,000 Conversion of securities
23/02/22 Paul Jones Buy +4,016 $4.98 $20,000 Conversion of securities
23/02/22 Paul Jones Exercise 4,016 $4.98 $20,000 Conversion of securities
23/02/22 Jennifer (Jenny) Macdonald Buy +6,024 $4.98 $30,000 Conversion of securities
23/02/22 Jennifer (Jenny) Macdonald Exercise 6,024 $4.98 $30,000 Conversion of securities
23/02/22 Kathryn (Kate) McKenzie Buy +1,004 $4.98 $5,000 Conversion of securities
23/02/22 Kathryn (Kate) McKenzie Exercise 1,004 $4.98 $5,000 Conversion of securities
19/11/21 Kathryn (Kate) McKenzie Issued 2,008 $4.98 $10,000 Directors' share plan
19/11/21 Jennifer (Jenny) Macdonald Issued 12,048 $4.98 $60,000 Directors' share plan
19/11/21 Paul Jones Issued 8,032 $4.98 $40,000 Directors' share plan
19/11/21 Robert Hubbard Issued 20,080 $4.98 $100,000 Directors' share plan
19/11/21 Sally Evans Issued 12,048 $4.98 $60,000 Directors' share plan
19/11/21 Gordon Davis Issued 16,064 $4.98 $80,000 Directors' share plan
08/11/21 Malcolm Parmenter Sell +143,193 $4.98 ($713,101) On-market trade
26/10/21 Kathryn (Kate) McKenzie Buy +2,000 $4.99 $9,980 On-market trade
20/10/21 Malcolm Parmenter Issued 101,034 $4.55 $459,704 Issue of securities
06/09/21 Malcolm Parmenter Expiry 80,498 $5.00 $402,490 As advised by the company
06/09/21 Malcolm Parmenter Issued 724,482 $5.00 $3,622,410 Conversion of securities
06/09/21 Malcolm Parmenter Exercise 724,482 $5.00 $3,622,410 Conversion of securities
01/09/21 Jennifer (Jenny) Macdonald Buy +10,000 $4.99 $49,900 On-market trade
01/09/21 Jennifer (Jenny) Macdonald Buy +10,000 $4.98 $49,800 On-market trade
31/08/21 Sally Evans Buy +7,173 $3.485 $24,997 Conversion of securities
31/08/21 Sally Evans Exercise 7,173 $3.485 $24,997 Conversion of securities
31/08/21 Robert Hubbard Buy +14,346 $3.482 $49,954 Conversion of securities
31/08/21 Robert Hubbard Exercise 14,346 $3.482 $49,954 Conversion of securities
31/08/21 Paul Jones Buy +5,738 $3.485 $19,999 Conversion of securities
31/08/21 Paul Jones Exercise 5,738 $3.485 $19,999 Conversion of securities
26/02/21 Kathryn (Kate) McKenzie Buy +2,500 $4.07 $10,175 On-market trade
25/02/21 Robert Hubbard Buy +7,172 $3.483 $24,977 Conversion of securities
25/02/21 Robert Hubbard Exercise 7,172 $3.483 $24,977 Conversion of securities
25/02/21 Sally Evans Buy +3,586 $3.485 $12,498 Conversion of securities
25/02/21 Sally Evans Exercise 3,586 $3.485 $12,498 Conversion of securities
10/12/20 Paul Jones Buy +2,869 $3.485 $9,999 Conversion of securities
10/12/20 Paul Jones Exercise 2,869 $3.485 $9,999 Conversion of securities
10/12/20 Sally Evans Issued 10,759 $3.485 $37,500 Directors' share plan
10/12/20 Robert Hubbard Issued 21,518 $3.485 $75,000 Directors' share plan
10/12/20 Paul Jones Issued 8,607 $3.486 $30,000 Directors' share plan
10/11/20 Jennifer (Jenny) Macdonald Buy +15,000 $3.51 $52,650 On-market trade
14/08/20 Malcolm Parmenter Expiry 475,180 $3.18 $1,511,072 As advised by the company
01/07/20 Malcolm Parmenter Exercise 26,537 $3.10 $82,264 Conversion of securities
01/07/20 Malcolm Parmenter Issued 26,537 $3.10 $82,264 Conversion of securities
03/03/20 Malcolm Parmenter Issued 11,081,391 $3.01 $33,354,987 Issue of options
25/11/19 Errol Katz Transfer 25,000 $3.04 $76,000 Off-market transfer
25/11/19 Errol Katz Transfer 25,000 $3.04 $76,000 Off-market transfer
13/09/19 Sally Evans Buy +15,000 $3.26 $48,900 On-market trade
19/08/19 Robert Hubbard Buy +25,000 $3.086 $77,150 On-market trade
Show All

Director Interests

The current holdings of HLS directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
John Mattick 31/03/2022 0 N/A N/A N/A
Sally Evans 23/02/2022 16,783 15,000 N/A N/A
Kathryn (Kate) McKenzie 23/02/2022 1,004 4,500 N/A N/A
Jennifer (Jenny) Macdonald 23/02/2022 41,024 N/A N/A N/A
Paul Jones 23/02/2022 12,623 40,588 0 N/A
Gordon Davis 23/02/2022 8,032 55,759 N/A N/A
Robert Hubbard 23/02/2022 31,558 76,951 N/A N/A
Malcolm Parmenter 08/11/2021 633,287 59,597 11,081,391 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 31, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 175,386,356 29.29%
Citicorp Nominees Pty Limited 112,031,380 18.71%
J P Morgan Nominees Australia Pty Limited 89,264,817 14.91%
National Nominees Pty Ltd 71,170,798 11.88%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 20,574,535 3.44%
Argo Investments Limited 16,320,664 2.73%
BNP Paribas Noms Pty Ltd <DRP> 11,463,079 1.91%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 10,184,406 1.70%
Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> 6,229,569 1.04%
Citicorp Nominees Pty Ltd <Colonial First State Inv A/C> 4,285,700 0.72%
RinRim Pty Ltd 2,392,047 0.40%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 1,761,260 0.29%
UBS Nominees Pty Ltd 1,057,466 0.18%
HSBC Custody Nominees (Australia) Limited <GSCO Customer A/C> 997,257 0.17%
AMP Life Limited 811,628 0.14%
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 799,450 0.13%
Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 784,767 0.13%
Joromada Pty Ltd 710,000 0.12%
Navigator Australia Ltd <MLC Investment Sett A/C> 708,490 0.12%
Merrill Lynch (Australia) Nominees Pty Limited 695,511 0.12%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 4,777 6,165 1,903 1,290 65 14,200

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Dimensional Entities 31/08/2021 30,485,918 6.04
Vinva Investment Management 28/02/2022 30,622,659 5.29
Australian Retirement Trust Pty Ltd 12/05/2022 30,839,249 5.33

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
12-05-22 Australian Retirement Trust Pty Ltd 30,839,249 -- 5.33
28-02-22 Vinva Investment Management 30,622,659 -- 5.29
22-07-21 Vinva Investment Management 31,595,448 -- 5.07

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
20-09-21 Vinva Investment Management 31,595,448 5.07 --
09-06-21 Yarra Capital Management Limited 32,925,092 5.28 --

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $4.58 30 June
2020 $3.05 30 June
2019 $3.02 28 June
2016 $0.005 28 June
2015 $0.003 30 June
2014 $0.006 30 June
HLS Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.